Could ibogaine offer a revolutionary long-term solution to addiction?

iStock-TARIK KIZILKAYA

Derived from the iboga plant, ibogaine is a psychoactive compound that could have huge potential as a long-term solution to addiction. ATAI Life Sciences and DemeRx are soon initiating clinical trials to test its efficacy.

According to the World Health Organization around 3.3 million people die every year from alcohol addiction and around 31 million have substance ...

Continue Reading →

Psychedelics Seek to Emulate Cannabis Rise to Social Acceptance #100954

For example, earlier this year, billionaires attending the World Economic Forum in Davos heard a pitch from a company developing a psychedelic drug to treat opioid addiction. In a report by Bloomberg from earlier this January, the Company Atai, backed by billionaire investor Peter Thiel, and partner DemeRx Inc., are preparing for a mid-stage trial of a synthetic form of the substance, called ibogaine, for treatment of drug addiction. Interest in such ...
Continue Reading →

Mind Medicine (MindMed) Inc adds new principal investigator and Swiss trial site as it expands Phase 2 study of microdosing LSD for adult ADHD

The Reno-based neuro-pharmaceutical firm’s microdosing division is expanding its slate of research and clinical trials

Mind Medicine (MindMed) Inc (NEO:MMED) () said it had appointed a world-leading psychedelics researcher as principal investigator for the first ever Phase 2a proof-of-concept clinical trial assessing lysergic acid diethylamide (LSD) to treat attention deficit hyperactivity disorder (ADHD) in adults.

It comes as the Reno-based neuro-pharmaceutical firm’s microdosing division, which is assessing consuming very low, sub-hallucinogenic doses of psychedelic substances, ...

Continue Reading →
Page 88 of 123 «...6070808687888990...»
UA-77446339-1